

Ming Jiang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5869574/publications.pdf>

Version: 2024-02-01

30
papers

531
citations

759233

12
h-index

677142

22
g-index

32
all docs

32
docs citations

32
times ranked

723
citing authors

#	ARTICLE	IF	CITATIONS
1	A 10-year survival update on early-stage extranodal natural killer/T-cell lymphoma with "sandwich"™ therapy. <i>Acta Oncologica</i> , 2022, 61, 611-614.	1.8	3
2	The value of prognostic nutritional index in nasal-type, extranodal natural killer/T-cell lymphoma. <i>Annals of Hematology</i> , 2022, 101, 1545-1556.	1.8	3
3	Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002). <i>Journal of Hematology and Oncology</i> , 2021, 14, 12.	17.0	40
4	WFDC Protein: A Promising Diagnosis Biomarker of Ovarian Cancer. <i>Journal of Cancer</i> , 2021, 12, 5404-5412.	2.5	9
5	Interleukin-36± suppresses growth of non-small cell lung cancer <i>in vitro</i> by reducing angiogenesis. <i>FEBS Open Bio</i> , 2021, 11, 1353-1363.	2.3	3
6	A phase II study of penpulimab, an anti-PD-1 antibody, in patients with relapsed or refractory classic Hodgkin lymphoma (cHL). <i>Journal of Clinical Oncology</i> , 2021, 39, 7529-7529.	1.6	11
7	How to Identify Patients at High Risk of Developing Nasal-Type, Extranodal Nature Killer/T-Cell Lymphoma-Associated Hemophagocytic Syndrome. <i>Frontiers in Oncology</i> , 2021, 11, 704962.	2.8	9
8	Unexpected Favorable Outcome to PD-1 Antibody Plus Lenvatinib in a Patient With Recurrent Intestinal Follicular Dendritic Cell Sarcoma: A Case Report and Literature Review. <i>Frontiers in Immunology</i> , 2021, 12, 653319.	4.8	7
9	Current Status of Out-of-Hospital Management of Cancer Patients and Awareness of Internet Medical Treatment: A Questionnaire Survey. <i>Frontiers in Public Health</i> , 2021, 9, 756271.	2.7	2
10	Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy. <i>Theranostics</i> , 2020, 10, 8382-8399.	10.0	42
11	791...A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with relapsed or refractory classic hodgkin lymphoma (cHL). , 2020, . .		1
12	PET/CT-based bone-marrow assessment shows potential in replacing routine bone-marrow biopsy in part of patients newly diagnosed with extranodal natural killer/T-cell lymphoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2529-2539.	2.5	9
13	Targeted demethylation of the SARI promotor impairs colon tumour growth. <i>Cancer Letters</i> , 2019, 448, 132-143.	7.2	31
14	CXCR2 is a novel cancer stem-like cell marker for triple-negative breast cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5559-5567.	2.0	14
15	Utilization of lung cancer cell lines for the study of lung cancer stem cells (Review). <i>Oncology Letters</i> , 2018, 15, 6791-6798.	1.8	13
16	A phase II prospective study of the "Sandwich" protocol, L-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 50155-50163.	1.8	28
17	Five-year analysis from phase 2 trial of "sandwich" chemoradiotherapy in newly diagnosed, stage I/II nasal type, extranodal natural killer/T-cell lymphoma. <i>Cancer Medicine</i> , 2016, 5, 33-40.	2.8	46
18	Antiangiogenic therapy using endostatin increases the number of ALDH+ lung cancer stem cells by generating intratumor hypoxia. <i>Scientific Reports</i> , 2016, 6, 34239.	3.3	10

#	ARTICLE	IF	CITATIONS
19	Silencing stem cell factor attenuates stemness and inhibits migration of cancer stem cells derived from Lewis lung carcinoma cells. <i>Tumor Biology</i> , 2016, 37, 7213-7227.	1.8	12
20	Body mass index as a prognostic factor in patients with extranodal natural killer/T-cell lymphoma, nasal type. <i>Oncotarget</i> , 2016, 7, 78159-78167.	1.8	4
21	Hypoxia and TGF- β 1 lead to endostatin resistance by cooperatively increasing cancer stem cells in A549 transplantation tumors. <i>Cell and Bioscience</i> , 2015, 5, 72.	4.8	14
22	Versican silencing improves the antitumor efficacy of endostatin by alleviating its induced inflammatory and immunosuppressive changes in the tumor microenvironment. <i>Oncology Reports</i> , 2015, 33, 2981-2991.	2.6	32
23	Treatment of nasopharyngeal carcinoma with pulmonary tuberculosis and gout: A case report. <i>Oncology Letters</i> , 2014, 8, 753-757.	1.8	3
24	Prognostic Characteristics of Gastrointestinal Tract NK/T-Cell Lymphoma. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, e74-e79.	2.2	25
25	Polarization of tumor-associated macrophage is associated with tumor vascular normalization by endostatin. <i>Thoracic Cancer</i> , 2013, 4, 295-305.	1.9	9
26	Phase 2 trial of "Sandwich" asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma. <i>Cancer</i> , 2012, 118, 3294-3301.	4.1	114
27	Low-dose endostatin normalizes the structure and function of tumor vasculature and improves the delivery and anti-tumor efficacy of cytotoxic drugs in a lung cancer xenograft murine model. <i>Thoracic Cancer</i> , 2012, 3, 229-238.	1.9	18
28	Gastrointestinal tract NK/t cell lymphoma: Clinical features, management, and prognosis of 47 patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, e18514-e18514.	1.6	0
29	Primary Central Nervous System Burkitt Lymphoma With Non-Immunoglobulin Heavy Chain Translocation in Right Ventricle: Case Report. <i>Pediatric Hematology and Oncology</i> , 2011, 28, 454-458.	0.8	13
30	A pilot study of weekly docetaxel chemotherapy combined with regional hyperthermia for pretreated stage III non-small cell lung cancer. <i>Chinese-German Journal of Clinical Oncology</i> , 2008, 7, 35-39.	0.1	0